Entospletinib in combination with obinutuzumab in R|R CLL

Adam Kittai, MD, Ohio State University, Columbus, OH, gave an overview of the phase I/II study of entospletinib in combination with obinutuzumab in patients with R/R chronic lymphocytic leukemia (CLL). This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

Format: Interview,Speaker: Adam Kittai,Event: iwCLL 2019,Subject: Chronic Lymphocytic Leukemia,Subject: Leukemia,Field: Disease Biology,Medicines: Entospletinib,Medicines: Obinutuzimab,